News
PHAR
13.34
+0.53%
0.07
Pharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target
TipRanks · 3d ago
Weekly Report: what happened at PHAR last week (0615-0619)?
Weekly Report · 4d ago
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
NASDAQ · 06/15 11:59
Weekly Report: what happened at PHAR last week (0608-0612)?
Weekly Report · 06/15 10:30
Weekly Report: what happened at PHAR last week (0601-0605)?
Weekly Report · 06/08 10:25
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 06/04 14:21
Pharming Group held annual shareholder meeting; resolutions won up to 99.95% support
PUBT · 06/04 12:41
Pharming Wins FDA Review for Joenja Pediatric sNDA in APDS
TipRanks · 06/04 10:40
Pharming Says FDA Accepts Joenja Application for Younger Children
Benzinga · 06/04 08:21
Pharming says FDA accepts Joenja sNDA resubmission for APDS in children aged 4-11
PUBT · 06/04 05:01
Pharming CEO to join Jefferies Global Healthcare Conference fireside chat
PUBT · 06/02 06:00
Weekly Report: what happened at PHAR last week (0525-0529)?
Weekly Report · 06/01 10:30
Pharming publishes presentation for 2026 annual shareholder meeting
PUBT · 05/29 17:31
Pharming posts presentation for 2026 annual shareholder meeting
PUBT · 05/28 15:19
Pharming Group appoints KPMG as new auditor as shareholders back full AGM agenda
TipRanks · 05/28 15:13
Pharming shareholders appoint KPMG as external auditor for 2026-2028
PUBT · 05/28 14:50
Pharming shareholders approve proposals at annual meeting
PUBT · 05/28 14:40
BlackRock discloses 12.43 million Pharming shares, 23.59 million voting rights
PUBT · 05/26 21:34
Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained
TipRanks · 05/26 10:26
Weekly Report: what happened at PHAR last week (0518-0522)?
Weekly Report · 05/25 10:34
More
Webull provides a variety of real-time PHAR stock news. You can receive the latest news about Pharming Group N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.